Global Zafirlukast Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Zafirlukast Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Zarlukast is a white solid with a melting point (º C) of 139. Its solubility is slightly soluble in methanol, soluble in tetrahydrofuran, acetone and dimethyl sulfoxide, and almost insoluble in water. Clinically, zarlukast is a leukotriene receptor antagonist, and its indication is the prevention and long-term treatment of asthma.
Zafirlukast report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Zafirlukast market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Leukotriene Antagonist and Treatment of Asthma are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Zafirlukast industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Zafirlukast key companies include Target Molecule Corp., Merck, Cayman Chemical Company, APExBIO Technology LLC, Carbosynth Ltd, Biorbyt, Toronto Research Chemicals, Glr Innovations and Medical Isotopes, Inc., etc. Target Molecule Corp., Merck, Cayman Chemical Company are top 3 players and held % share in total in 2022.
Zafirlukast can be divided into 10 mg and 20 mg, etc. 10 mg is the mainstream product in the market, accounting for % share globally in 2022.
Zafirlukast is widely used in various fields, such as Leukotriene Antagonist and Treatment of Asthma, etc. Leukotriene Antagonist provides greatest supports to the Zafirlukast industry development. In 2022, global % share of Zafirlukast went into Leukotriene Antagonist filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Zafirlukast market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Target Molecule Corp.
Merck
Cayman Chemical Company
APExBIO Technology LLC
Carbosynth Ltd
Biorbyt
Toronto Research Chemicals
Glr Innovations
Medical Isotopes, Inc.
AvaChem Scientific
Tokyo Chemical Industry Co.,Ltd.
Carbone scientific
Santa Cruz Biotechnology, Inc.
Chemos GmbH and Co. KG
3B Scientific
MedChemExpress LLC
AK Scientific, Inc.
CarboMer, Inc.
Creative Enzymes
Combi-Blocks
Chromo Laboratories India Pvt Ltd
Dr.Reddy's Laboratories Limited
Shanghai Beilang Biotechnology Co., Ltd
Shanghai Yuanye Bio-Technology Co., Ltd
Shanghai Acmec Biochemical Co.,Ltd
Shanghai McLin Biochemical Technology Co., Ltd
Dalian Meilun Biotechnology Co., Ltd
BOC Sciences
Standardpharm Co., Ltd.
Aibixin (Shanghai) Biotechnology Co., Ltd
Glpbio
Abmole Bioscience Inc.
Segment by Type
10 mg
20 mg
Leukotriene Antagonist
Treatment of Asthma
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Zafirlukast market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Zafirlukast introduction, etc. Zafirlukast Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Zafirlukast market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Zafirlukast report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Zafirlukast market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Leukotriene Antagonist and Treatment of Asthma are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Zafirlukast industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Zafirlukast key companies include Target Molecule Corp., Merck, Cayman Chemical Company, APExBIO Technology LLC, Carbosynth Ltd, Biorbyt, Toronto Research Chemicals, Glr Innovations and Medical Isotopes, Inc., etc. Target Molecule Corp., Merck, Cayman Chemical Company are top 3 players and held % share in total in 2022.
Zafirlukast can be divided into 10 mg and 20 mg, etc. 10 mg is the mainstream product in the market, accounting for % share globally in 2022.
Zafirlukast is widely used in various fields, such as Leukotriene Antagonist and Treatment of Asthma, etc. Leukotriene Antagonist provides greatest supports to the Zafirlukast industry development. In 2022, global % share of Zafirlukast went into Leukotriene Antagonist filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Zafirlukast market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Target Molecule Corp.
Merck
Cayman Chemical Company
APExBIO Technology LLC
Carbosynth Ltd
Biorbyt
Toronto Research Chemicals
Glr Innovations
Medical Isotopes, Inc.
AvaChem Scientific
Tokyo Chemical Industry Co.,Ltd.
Carbone scientific
Santa Cruz Biotechnology, Inc.
Chemos GmbH and Co. KG
3B Scientific
MedChemExpress LLC
AK Scientific, Inc.
CarboMer, Inc.
Creative Enzymes
Combi-Blocks
Chromo Laboratories India Pvt Ltd
Dr.Reddy's Laboratories Limited
Shanghai Beilang Biotechnology Co., Ltd
Shanghai Yuanye Bio-Technology Co., Ltd
Shanghai Acmec Biochemical Co.,Ltd
Shanghai McLin Biochemical Technology Co., Ltd
Dalian Meilun Biotechnology Co., Ltd
BOC Sciences
Standardpharm Co., Ltd.
Aibixin (Shanghai) Biotechnology Co., Ltd
Glpbio
Abmole Bioscience Inc.
Segment by Type
10 mg
20 mg
Segment by Application
Leukotriene Antagonist
Treatment of Asthma
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Zafirlukast market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Zafirlukast introduction, etc. Zafirlukast Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Zafirlukast market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices